What happened?
A number of stocks jumped in the afternoon session after election results confirmed that Democrats reclaimed majorities in the House and Senate, easing regulatory uncertainty around drug pricing policy.
As reported by CNBC, Wall Street analysts project that the biopharmaceutical sector's recovery will strengthen in the wake of the congressional election outcome. Investors had feared potential disruptions to healthcare policies, but analysts noted that drug pricing legislation is unlikely to dominate the new legislative agenda. Prior statutory frameworks already established expanding annual Medicare price negotiations, meaning existing government policies will remain intact without unexpected new restrictions.
Furthermore, broader equity markets and index futures rebounded as investors interpreted the shifting balance of power in Washington as a stabilizing dynamic. The presence of congressional checks and balances is widely viewed by market strategists as a moderating force on executive policy decisions, creating a predictable regulatory climate that supports ongoing investments across pharmaceutical and biotechnology developers.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.
Among others, the following stocks were impacted:
- Senior health, home health & hospice company AdaptHealth (NASDAQ: AHCO) jumped 17.7%. Is now the time to buy AdaptHealth? Access our full analysis report here, it’s free.
- Dental equipment & technology company Align Technology (NASDAQ: ALGN) jumped 9.8%. Is now the time to buy Align Technology? Access our full analysis report here, it’s free.
- Hospital chains company Acadia Healthcare (NASDAQ: ACHC) jumped 10.5%. Is now the time to buy Acadia Healthcare? Access our full analysis report here, it’s free.
- Patient monitoring company DexCom (NASDAQ: DXCM) jumped 6.5%. Is now the time to buy DexCom? Access our full analysis report here, it’s free.
- Surgical equipment & consumables - diversified company STERIS (NYSE: STE) jumped 7.6%. Is now the time to buy STERIS? Access our full analysis report here, it’s free.
Zooming in on AdaptHealth (AHCO)
AdaptHealth’s shares are very volatile and have had 21 moves greater than 5% over the last year. But moves this big are rare even for AdaptHealth and indicate this news significantly impacted the market’s perception of the business.
The biggest move we wrote about over the last year was 3 months ago when the stock dropped 39.5% on the news that the company reported disappointing second-quarter results and significantly cut its full-year financial guidance. The home medical equipment provider posted a loss of $0.99 per share, a stark contrast to analyst estimates for a $0.15 gain. Revenue for the quarter was $740.3 million, falling short of the expected $847.2 million.
Looking ahead, AdaptHealth slashed its 2026 revenue guidance to a new midpoint of $2.87 billion, a significant reduction from its previous forecast of $3.49 billion and well below Wall Street's expectations. The company also cut its adjusted EBITDA outlook to a range of $490 million to $520 million. The company attributed the lowered outlook to challenges with a West Coast partnership and an unexpected price increase from a manufacturer.
AdaptHealth is down 22.8% since the beginning of the year, and at $7.47 per share, it is trading 44.2% below its 52-week high of $13.38 from April 2026. Investors who bought $1,000 worth of AdaptHealth’s shares 5 years ago would now be looking at only $288.78.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
